Fibroblast Growth Factor 23 and the Antiproteinuric Response to Dietary Sodium Restriction During Renin-Angiotensin-Aldosterone System Blockade

1997, Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy, Lancet, 349, 1857, 10.1016/S0140-6736(96)11445-8 Giatras, 1997, Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. angiotensin-converting-enzyme inhibition and progressive renal disease study group, Ann Intern Med, 127, 337, 10.7326/0003-4819-127-5-199709010-00001 Schmieder, 2011, Changes in albuminuria predict mortality and morbidity in patients with vascular disease, J Am Soc Nephrol, 22, 1353, 10.1681/ASN.2010091001 Ruggenenti, 2003, Retarding progression of chronic renal disease: the neglected issue of residual proteinuria, Kidney Int, 63, 2254, 10.1046/j.1523-1755.2003.00033.x Laverman, 2002, Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy?, J Renin Angiotensin Aldosterone Syst, 3, 205, 10.3317/jraas.2002.042 Lambers Heerspink, 2013, Improving the efficacy of RAAS blockade in patients with chronic kidney disease, Nat Rev Nephrol, 9, 112, 10.1038/nrneph.2012.281 Vogt, 2008, Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan, J Am Soc Nephrol, 19, 999, 10.1681/ASN.2007060693 Hung, 2014, Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease, Kidney Int, 85, 703, 10.1038/ki.2013.336 Zoccali, 2011, Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition, J Am Soc Nephrol, 22, 1923, 10.1681/ASN.2011020175 Isakova, 2011, Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease, Kidney Int, 79, 1370, 10.1038/ki.2011.47 Gutierrez, 2008, Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis, N Engl J Med, 359, 584, 10.1056/NEJMoa0706130 Fliser, 2007, Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study, J Am Soc Nephrol, 18, 2600, 10.1681/ASN.2006080936 Isakova, 2011, Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease, JAMA, 305, 2432, 10.1001/jama.2011.826 Wolf, 2011, Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality, J Am Soc Nephrol, 22, 956, 10.1681/ASN.2010080894 Ix, 2010, Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study, Nephrol Dial Transplant, 25, 993, 10.1093/ndt/gfp699 Vervloet, 2012, Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: an analysis of the MASTERPLAN cohort, BMC Nephrol, 13, 20, 10.1186/1471-2369-13-20 Lundberg, 2012, FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy, Clin J Am Soc Nephrol, 7, 727, 10.2215/CJN.10331011 Baia, 2013, Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation, Clin J Am Soc Nephrol, 8, 1968, 10.2215/CJN.01880213 Scialla, 2014, Fibroblast growth factor-23 and cardiovascular events in CKD, J Am Soc Nephrol, 25, 349, 10.1681/ASN.2013050465 Ix, 2012, Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study), J Am Coll Cardiol, 60, 200, 10.1016/j.jacc.2012.03.040 Slagman, 2011, Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial, BMJ, 343, d4366, 10.1136/bmj.d4366 Doorenbos, 2012, Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease, J Steroid Biochem Mol Biol, 128, 56, 10.1016/j.jsbmb.2011.09.002 Trenkel, 2002, Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism, Exp Clin Endocrinol Diabetes, 110, 80, 10.1055/s-2002-23491 Buter, 1998, The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide, Nephrol Dial Transplant, 13, 1682, 10.1093/ndt/13.7.1682 Esnault, 2005, Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents, J Am Soc Nephrol, 16, 474, 10.1681/ASN.2004060505 Ekinci, 2009, Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake, Diabetes Care, 32, 1398, 10.2337/dc08-2297 Andrukhova, 2012, FGF23 regulates renal sodium handling and blood pressure, J Am Soc Nephrol, 23, 46A Kramer, 2003, Inter-individual differences in anti-proteinuric response to ACEi in established Adriamycin nephrotic rats are predicted by pretreatment renal damage, J Pathol, 201, 160, 10.1002/path.1405 Lindberg K, Amin R, Moe OW, et al. The kidney is the principal organ mediating klotho effects [published online ahead of print May 22, 2014]. J Am Soc Nephrol. http://dx.doi.org/10.1681/ASN.2013111209. Shimada, 2005, Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism, Am J Physiol Renal Physiol, 289, F1088, 10.1152/ajprenal.00474.2004 de Borst, 2011, Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease, J Am Soc Nephrol, 22, 1603, 10.1681/ASN.2010121251 Hamming, 2007, The emerging role of ACE2 in physiology and disease, J Pathol, 212, 1, 10.1002/path.2162 Lely, 2004, Renal ACE2 expression in human kidney disease, J Pathol, 204, 587, 10.1002/path.1670 Dai, 2012, A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model, PLoS One, 7, e44161, 10.1371/journal.pone.0044161 National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease: guideline 9 pharmacological therapy: nondiabetic kidney disease. http://www.ajkd.org/article/S0272-6386%2804%2900272-0/fulltext#Guideline%209:%20pharmacological%20therapy:%20nondiabetic%20kidney%20disease. Updated 2004. Accessed August 3, 2012.